About this FactMed analysis covering adverse side effect reports of AMARYL (GLIMEPIRINE) (GLIMEPRIRIDE) patients who developed DEHYDRATION.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 1 individuals taking AMARYL (GLIMEPIRINE) (GLIMEPRIRIDE) reported DEHYDRATION to the FDA. A total of 1 AMARYL (GLIMEPIRINE) (GLIMEPRIRIDE) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between AMARYL (GLIMEPIRINE) (GLIMEPRIRIDE) and DEHYDRATION. In doing so, we compare AMARYL (GLIMEPIRINE) (GLIMEPRIRIDE) with other drugs that cause DEHYDRATION, to help you evaluate whether or not AMARYL (GLIMEPIRINE) (GLIMEPRIRIDE) causes DEHYDRATION. Likewise, this page shows the most highly-reported side effects of AMARYL (GLIMEPIRINE) (GLIMEPRIRIDE), so you can see if DEHYDRATION ranks among AMARYL (GLIMEPIRINE) (GLIMEPRIRIDE)'s most well-known side effects.
Summary Statistics
Reports of AMARYL (GLIMEPIRINE) (GLIMEPRIRIDE) causing DEHYDRATION: 1
Reports of any side effect of AMARYL (GLIMEPIRINE) (GLIMEPRIRIDE) : 1
Percentage of AMARYL (GLIMEPIRINE) (GLIMEPRIRIDE) patients where DEHYDRATION is a reported side effect: 100.0000%

FDA reports of any drug causing DEHYDRATION : 51306
Average percentage for all medicated patients where DEHYDRATION is reported as a complication: 0.3216%

Physician opinion on AMARYL (GLIMEPIRINE) (GLIMEPRIRIDE) as adverse event culprit:

Overall opinion for all reports of this drug:
Most frequent diagnoses/indications for prescribing AMARYL (GLIMEPIRINE) (GLIMEPRIRIDE):
( 0 patients )
Drugs with high FDA adverse event association with DEHYDRATION:

ASPIRIN (4930 patients)
LASIX (2777 patients)
FOSAMAX (2721 patients)
CISPLATIN (2627 patients)
LISINOPRIL (2455 patients)
PREDNISONE (2354 patients)
FUROSEMIDE (2149 patients)
AVONEX (1976 patients)
OMEPRAZOLE (1955 patients)
DEXAMETHASONE (1940 patients)
VIOXX (1899 patients)
LIPITOR (1863 patients)
ZOMETA (1861 patients)
CARBOPLATIN (1841 patients)
FLUOROURACIL (1836 patients)
ZOFRAN (1765 patients)
NEXIUM (1763 patients)
COUMADIN (1666 patients)
FOLIC ACID (1637 patients)
ACETAMINOPHEN (1576 patients)
HEPARIN SODIUM INJECTION (1574 patients)
ATENOLOL (1559 patients)
SEROQUEL (1554 patients)
DIGOXIN (1534 patients)
SYNTHROID (1534 patients)
HYDROCHLOROTHIAZIDE (1517 patients)
SIMVASTATIN (1475 patients)
POTASSIUM CHLORIDE (1419 patients)
PROTONIX (1403 patients)
PRILOSEC (1374 patients)
RIBAVIRIN (1362 patients)
FORTEO (1351 patients)
HUMIRA (1329 patients)
ALLOPURINOL (1319 patients)
METFORMIN HCL (1317 patients)
REVLIMID (1310 patients)
NEURONTIN (1291 patients)
XANAX (1270 patients)
AMBIEN (1269 patients)
PLAVIX (1262 patients)
OXYCONTIN (1260 patients)
REMICADE (1234 patients)
NORVASC (1231 patients)
LEVOTHYROXINE SODIUM (1228 patients)
COMPAZINE (1220 patients)
LORAZEPAM (1218 patients)
ATIVAN (1218 patients)
ZOLOFT (1176 patients)
ZOCOR (1173 patients)
PEG-INTRON (1164 patients)
OXALIPLATIN (1098 patients)
DECADRON (1088 patients)
IBUPROFEN (1063 patients)
CAPECITABINE (1060 patients)
ACCUTANE (1059 patients)
LANTUS (1015 patients)
ALBUTEROL (1004 patients)
TOPROL-XL (1000 patients)
PREDNISOLONE (989 patients)
VITAMIN D (976 patients)
LEXAPRO (973 patients)
PREVACID (972 patients)
SPIRONOLACTONE (956 patients)
METHOTREXATE (955 patients)
XELODA (947 patients)
DIANEAL (943 patients)
AVASTIN (939 patients)
METOPROLOL TARTRATE (936 patients)
BEVACIZUMAB (926 patients)
PACLITAXEL (926 patients)
PERCOCET (923 patients)
PREDNISONE TAB (922 patients)
CETUXIMAB (897 patients)
MORPHINE (893 patients)
OXYCODONE HCL (889 patients)
LYRICA (879 patients)
VICODIN (876 patients)
DIOVAN (870 patients)
BYETTA (861 patients)
AREDIA (836 patients)
LEVAQUIN (835 patients)
CELEBREX (809 patients)
DOCETAXEL (809 patients)
TAXOL (805 patients)
AMLODIPINE (803 patients)
TYSABRI (789 patients)
RADIATION THERAPY (787 patients)
GABAPENTIN (777 patients)
WARFARIN SODIUM (777 patients)
CALCIUM (775 patients)
DURAGESIC-100 (774 patients)
CYMBALTA (769 patients)
ALDACTONE (765 patients)
MULTI-VITAMINS (762 patients)
CYCLOPHOSPHAMIDE (756 patients)
VELCADE (749 patients)
COREG (740 patients)
TAXOTERE (734 patients)
INSULIN (725 patients)
PAXIL (722 patients)
RAMIPRIL (719 patients)
ONDANSETRON (716 patients)
METOCLOPRAMIDE (710 patients)
CRESTOR (708 patients)
FENTANYL (705 patients)
VITAMIN B-12 (701 patients)
ALPRAZOLAM (695 patients)
EXJADE (682 patients)
LEUCOVORIN CALCIUM (680 patients)
IMODIUM (656 patients)
ENALAPRIL MALEATE (653 patients)
TRAMADOL HCL (643 patients)
MULTI-VITAMIN (642 patients)
GLUCOPHAGE (641 patients)
LANSOPRAZOLE (641 patients)
ZYPREXA (640 patients)
METOPROLOL (633 patients)
PEGASYS (633 patients)
MORPHINE SULFATE (626 patients)
EFFEXOR (626 patients)
BENADRYL (621 patients)
REGLAN (614 patients)
SUTENT (603 patients)
ZANTAC (598 patients)
LORTAB (598 patients)
LOVENOX (596 patients)
CLONAZEPAM (595 patients)
COLACE (593 patients)
ADVAIR DISKUS 100/50 (589 patients)
CIPROFLOXACIN (587 patients)
NITROGLYCERIN (586 patients)
DILAUDID (584 patients)
FLUCONAZOLE (582 patients)
ALTACE (579 patients)
MEGACE (577 patients)
ARANESP (575 patients)
RISPERDAL (569 patients)
PROZAC (548 patients)
BACTRIM (545 patients)
RANITIDINE (537 patients)
ACYCLOVIR (534 patients)
LOPRESSOR (533 patients)
SANDOSTATIN LAR (530 patients)
IRINOTECAN HCL (530 patients)
COZAAR (526 patients)
LOMOTIL (526 patients)
ENBREL (526 patients)
REBIF (525 patients)
PREMARIN (522 patients)
SPIRIVA (517 patients)
TRAZODONE HCL (517 patients)
DOXORUBICIN HCL (515 patients)
ERBITUX (515 patients)
NEXAVAR (513 patients)
METFORMIN (509 patients)
CALCIUM CARBONATE (507 patients)
FLOMAX (505 patients)
PEPCID (502 patients)
CELEXA (500 patients)
TYLENOL (499 patients)
FERROUS SULFATE TAB (496 patients)
PANTOPRAZOLE (494 patients)
AMOXICILLIN (488 patients)
ACTOS (482 patients)
REBETOL (481 patients)
WELLBUTRIN (478 patients)
FAMOTIDINE (474 patients)
NYSTATIN (473 patients)
GLYBURIDE (472 patients)
NOVOLOG (460 patients)
ASCORBIC ACID (458 patients)
CARVEDILOL (454 patients)
SINGULAIR (453 patients)
VINCRISTINE (453 patients)
PROMETHAZINE (453 patients)
NEUPOGEN (452 patients)
LACTULOSE (451 patients)
MIRALAX (451 patients)
HUMALOG (449 patients)
GLIPIZIDE (449 patients)
AMITRIPTYLINE HCL (443 patients)
MS CONTIN (443 patients)
PHENERGAN (442 patients)
VALIUM (441 patients)
PROCHLORPERAZINE (433 patients)
MYCOPHENOLATE MOFETIL (432 patients)
MAGNESIUM OXIDE (431 patients)
PANITUMUMAB (430 patients)
IRON (429 patients)
CIPRO (422 patients)
LAPATINIB (421 patients)
EXELON (419 patients)
METOPROLOL SUCCINATE (416 patients)
ALLEGRA (414 patients)
DIFLUCAN (411 patients)
CYCLOSPORINE (411 patients)
FLEXERIL (410 patients)
ACTONEL (407 patients)
TYLENOL (CAPLET) (407 patients)
DIAZEPAM (406 patients)
ZYRTEC (405 patients)
SORAFENIB (398 patients)
CLOZARIL (396 patients)
KLONOPIN (393 patients)
PANTOPRAZOLE SODIUM (393 patients)
GEMCITABINE (392 patients)
ARICEPT (388 patients)
SODIUM CHLORIDE (385 patients)
DEXAMETHASONE TAB (384 patients)
CLONIDINE (383 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.


Recent FactMed Activity for AMARYL (GLIMEPIRINE) (GLIMEPRIRIDE)


Issue Description / Topic Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about DEHYDRATION and AMARYL (GLIMEPIRINE) (GLIMEPRIRIDE), post it here. You may receive a response from a fellow patient - or a leading expert in the field.
Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking AMARYL (GLIMEPIRINE) (GLIMEPRIRIDE), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.
Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in AMARYL (GLIMEPIRINE) (GLIMEPRIRIDE). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.
We are currently accepting registration for AMARYL (GLIMEPIRINE) (GLIMEPRIRIDE) experts. If you are a healthcare provider experienced in prescribing AMARYL (GLIMEPIRINE) (GLIMEPRIRIDE), please register here.
© 2014 FactMed, Inc
Privacy Policy
Terms of Use